June 4, 2020, Baltimore, Md. – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, is one of just 10 life science companies selected this year for Springboard Enterprises’ Health Innovation Hub: Life Science. Elaine Haynes, president and CEO of KaloCyte, will join more than 800 experienced “been there, run that” entrepreneurs who make up the Springboard Expert Network.
“I’m thrilled to represent KaloCyte as part of the 2020 Springboard Health Innovation Hub cohort,” said Haynes. “The focus of the program and its significant resources and network will only advance the growth of our company, and its primary product ErythroMer™, a potential life-saving blood substitute that is a universal option for all blood types.” Haynes noted that the COVID-19 pandemic highlights the tenuous nature of the blood supply system, “making KaloCyte’s mission even more critical.”
“Investors say they like to bet on the jockey not the horse,” said Kay Koplovitz, CEO of Koplovitz and Co. and Chairman of Springboard Enterprises. “This year we are betting our human capital on an impressive group of experienced entrepreneurial women who will not only benefit from the talent in our expert network, but also add immeasurably to it.”
This year’s cohort will convene virtually over the next several months for the Health Innovation Hub Bootcamp, after which they are matched with a personal advisory team, tasked with providing a meaningful impact on the company’s next stage of growth. Companies recruited and qualified by Springboard’s network of advisors are among the most promising companies led by some of the most talented and accomplished women entrepreneurs.
Since 2000, Springboard has become a human capital powerhouse connecting growth-stage companies with investors, advisors and lucrative business opportunities. KaloCyte joins the ranks of globally recognized brands including Achillion, AskBio, Xenogen, ViaCord, ZipCar, Constant Contact, and MinuteClinic.
About KaloCyte
KaloCyte, a preclinical-stage healthcare biotechnology company, was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care. The company is poised to deliver ErythroMer, a freeze-dried, bio-inspired synthetic red blood cell, to market, with the expectation of starting human trials in two to three years. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte, supported by nearly $7M in federal awards and investor funding, is a University of Maryland BioPark affiliate company located in Baltimore, Maryland. Learn more at www.kalocyte.com.
About Springboard Enterprises
Springboard Enterprises’ mission is to accelerate the growth of entrepreneurial companies led by women through access to essential resources and a global community of experts. It is the leading network of influencers investors and innovators dedicated to building high-growth companies led by women who are transforming industries in technology and life science. The measure of our success is in the results. Since 2000, over 800 Springboard portfolio companies seeking investment of financial and human capital for product development and expansion have created $20 Billion in value via equity investments, IPOs and mergers and acquisitions. Springboard entrepreneurs are transforming industries.
Media Contacts
KaloCyte, Inc. | Darci Bartlett | 410-706-7066 or dbartlett@kalocyte.com
Springboard Enterprises | Sierra Hieronymus | sierra@sb.co